Dimebon, an investigational drug co-developed by Pfizer and Medivation, failed its Phase III trial in Alzheimer’s disease. The compound failed to meet its co-primary and secondary efficacy endpoints — cognition and global function — compared to placebo in the CONNECTION trial. Dimebon was well-tolerated in its separate Phase III safety and tolerability study, when dosed alone or in combination with approved Alzheimer’s medicines. “We are evaluating the CONNECTION data with M...